title: More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.
authors.forename: Chen-Tian
authors.initials: CT
authors.lastname: Shen
authors.forename: Zhong-Ling
authors.initials: ZL
authors.lastname: Qiu
authors.forename: Quan-Yong
authors.initials: QY
authors.lastname: Luo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib